Drug Trial Radar · NCT05367778
Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
176
Planned (sponsor's estimate)
Start
Jun 3, 2022
Primary completion
Apr 30, 2025
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.
Conditions
- Advanced Solid Tumor
Interventions
HS-10370Drug
HS-10370 will be administered orally once daily in a continuous regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia:To determine the maximum tolerated dose (MTD)Time frame: From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (28 days).
- 2. Phase Ib/II: To evaluate clinical activity/efficacy of HS-10370 by assessment of objective response rateTime frame: up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.